( ALAMEDA Calif.--(BUSINESS WIRE)--Jun 2...)Advanced Cell Technology Develops First Human Embryonic Stem Cell,Line without Destroying an Embryo,Health

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced Cell Technology, Inc. (OTCBB: ACTC) has successfully produced a human embryonic stem cell (hESC) line without destroying an embryo at its lab in Worcester, Massachusetts. This development was announced by Robert Lanza, M.D., V.P. of Research and Scientific Development of Advanced Cell Technology (ACT) on Tuesday at the fifth annual meeting of the International Society for Stem Cell Research (ISSCR) in Cairns, Australia.

In August 2006, ACT published a paper in Nature Magazine documenting a technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple hESCs without destroying the embryo.

At the ISSCR meeting, Dr. Lanza definitively announced that he and his team have now reproduced the work of removing a single cell blastomere from a human embryo with the surviving embryo cryo-preserved. Dr. Lanza noted at the meeting, "These are the first human embryonic stem cells in existence to be made without destroying an embryo."

This development comes on the heels of President Bush's veto of federal legislation which would have provided funding for embryonic stem cell research.

In an appearance yesterday on Bloomberg Television's "On the Economy," juxtaposed with the President's press conference relating to his stem cell funding veto, William M. Caldwell, IV, Chairman and CEO of ACT, commented on ACT's single cell blastomere development: "It does address the President's concern. We're very excited about this technology, and we're using it today to develop treatments for (addressing) macular degeneration."

Today Mr. Caldwell said, "The American people spoke through their representatives in Congress when federal funding legislation was passed by both houses and presented to the President. We are, of course, very disappointed with his veto yesterday. Our single cell b
'"/>

Page: 1 2 3
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma